Compare DAC & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | NBTX |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | Greece | France |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.8B |
| IPO Year | 2006 | 2018 |
| Metric | DAC | NBTX |
|---|---|---|
| Price | $129.51 | $41.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $112.50 | $36.00 |
| AVG Volume (30 Days) | 72.6K | ★ 82.8K |
| Earning Date | 05-14-2026 | 03-31-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $58.17 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $83.56 | $4.93 |
| 52 Week High | $135.21 | $57.14 |
| Indicator | DAC | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 58.42 |
| Support Level | $121.29 | $38.89 |
| Resistance Level | $134.25 | $42.40 |
| Average True Range (ATR) | 2.75 | 2.28 |
| MACD | 0.62 | 0.47 |
| Stochastic Oscillator | 84.46 | 80.61 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia, Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments: Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.